Bilateral acute simultaneous onset anterior uveitis presumed secondary to erlotinib: A report of two cases.

Autor:	Klein KA; Department of Ophthalmology, New England Eye Center, Tufts Medical Center, Boston, MA, USA., Azzoli CG; Department of Ophthalmology, New England Eye Center, Tufts Medical Center, Boston, MA, USA., Rifkin LM; Department of Ophthalmology, New England Eye Center, Tufts Medical Center, Boston, MA, USA.
Jazyk:	angličtina
Zdroj:	American journal of ophthalmology case reports [Am J Ophthalmol Case Rep] 2016 Sep 10; Vol. 6, pp. 21-23. Date of Electronic Publication: 2016 Sep 10 (Print Publication: 2017).
DOI:	10.1016/j.ajoc.2016.09.003
Abstrakt:	Purpose: To report two new cases of presumed erlotinib-associated bilateral acute simultaneous-onset anterior uveitis effectively treated with topical steroids. Observations: Two patients were referred to the uveitis clinic with bilateral acute simultaneous onset, anterior uveitis six weeks after starting the chemotherapeutic agent erlotinib. Frequent topical steroid were started and the inflammation responded swiftly and completely. Conclusions and Importance: Bilateral acute simultaneous onset anterior uveitis is a potential side effect associated with erlotinib use that has not been well described. Physicians should be aware of this potential association in patients with recent treatment with erlotinib who complain of blurred vision, photophobia, or redness of the eyes. In some cases, the inflammation responds well to topical therapy and medication can be continued.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu